Quantcast

Latest Sunitinib Stories

2008-08-08 00:00:11

By JEREMY LAURANCE The big question Why are we asking this now? CANCER CHARITIES, kidney specialists and campaigners were outraged yesterday when the National Institute for Clinical Excellence (Nice), announced that it had rejected four new drugs for advanced kidney cancer as too expensive for the NHS. In draft guidance, the medicines watchdog said that the drugs can extend life by five to six months on average but they cost too much. The money would do more good if it were spent...

2008-08-07 18:00:00

By JANE KIRBY PATIENTS with advanced kidney cancer will be denied four treatments on the NHS under new guidelines published yesterday. The National Institute for Health and Clinical Excellence (Nice) issued draft guidance rejecting the drugs Sutent (sunitinib), Avastin (bevacizumab), Nexavar (sorafenib) and Torisel (temsirolimus). Primary care trusts in Merseyside and Cheshire had already agreed to start offering Sutent on the NHS, as reported by the Daily Post in December last year....

2008-08-07 18:00:00

By Greg Tindle A WELSH cancer expert has described as "an outrage" plans to deny patients with advanced kidney cancer four types of drug treatment on the NHS. Under new guidelines the National Institute for Health and Clinical Excellence (Nice) - the Government's medicines watchdog - has turned down the use of the drugs saying they are not cost effective. Charities have expressed concern at the decision, saying it has left patients only one treatment option - interferon - to which...

2008-08-07 18:00:23

By Emma Brady Midland cancer experts have hit out at a decision to deny kidney cancer patients four drugs under new NHS guidelines issued yesterday. The National Institute for Health and Clinical Excellence (Nice) issued draft guidance rejecting the drugs Sutent (sunitinib), Avastin (bevacizumab), Nexavar (sorafenib) and Torisel (temsirolimus) which cost between pounds 20,000 and pounds 35,000 per patient per year. This leaves just one cancer drug, interferon, to which many patients...

2008-08-07 18:00:00

By HELEN RAE PATIENTS with advanced kidney cancer will be denied four life- extending treatments on the NHS because they are not cost effective. The National Institute for Health and Clinical Excellence (Nice) yesterday issued draft guidance rejecting the drugs Sutent (Sunitinib), Avastin, Nexavar and Torisel. Charities expressed outrage at the decision, saying it left patients only one treatment option - Interferon - to which many do not respond. Cancer sufferer Ken Potts, 55, of...

2008-08-07 12:00:18

PATIENTS with advanced kidney cancer will be denied four treatments on the NHS under new guidelines published today. The National Institute for Health and Clinical Excellence (Nice) issued draft guidance rejecting the drugs Sutent (sunitinib), Avastin (bevacizumab), Nexavar (sorafenib) and Torisel (temsirolimus). Charities expressed outrage at the decision, saying it left patients only one treatment option - interferon - to which many do not respond. Professor John Wagstaff, from the...

2008-08-07 12:00:18

By JANE KIRBY Broadcaster James Whale accused a health watchdog today of being "barbaric" in denying kidney cancer patients access to four drugs. The star, who was diagnosed with the disease in 2000 and set up a charity to raise awareness, said the National Institute for Health and Clinical Excellence (Nice) was a "very badly named organisation". He slammed Nice's decision - which is subject to appeal - to deny patients access to Sutent (sunitinib), Avastin (bevacizumab), Nexavar...

2008-08-07 09:10:00

By Barry Nelson PATIENTS with advanced kidney cancer were dealt a devastating blow last night when spending watchdogs effectively banned four life- giving drugs on the NHS. The National Institute for Health and Clinical Excellence (Nice) issued draft guidance rejecting the drugs Sutent, Avastin, Nexavar and Torisel as too expensive. Charities expressed outrage at the decision, saying it left patients only one treatment option ? interferon ? which is not as effective for many sufferers....

2008-08-04 15:00:16

By Ashley Andyshak, The Frederick News-Post, Md. Aug. 2--Frederick Memorial Hospital Regional Cancer Therapy Center has received a $30,000 grant to improve its clinical research programs. The cancer center is one of three facilities in the nation to receive the newly established Community Oncology Research Award from the American Society of Clinical Oncology. Dr. P. Gregory Rausch of Oncology Care Associates said the money will be used to increase awareness of trials available in the...

2008-07-29 12:00:33

Bayer HealthCare Pharmaceuticals and Onyx Pharmaceuticals have announced that the State Food and Drug Administration of China has approved Nexavar tablets for the treatment of patients with unresectable or metastatic hepatocellular carcinoma, or liver cancer. The approval was based on two international Phase III double-blind, placebo-controlled trials that evaluated more than 800 patients who received no prior systemic therapy. Nexavar targets both the tumor cell and tumor vasculature....


Word of the Day
jument
  • A beast of burden; also, a beast in general.
'Jument' ultimately comes from the Latin 'jugum,' yoke.
Related